PGR and breast cancer: Currently, BC is characterized not only by clinical staging and pathological grading, but also by molecular hallmarks: cell proliferation marker Ki-67 and other markers, i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [3].